Lupin receives US FDA approval for modafinil tablets

Lupin Limited received US FDA approval for its modafinil tablets USP, 100 mg and 200 mg, as bioequivalent to Provigil tablets by Nuvo Pharmaceuticals. The approval allows Lupin to market modafinil for excessive sleepiness conditions in the US, with Provigil's market valued at approximately USD 70.7 million annually.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it.